Find recruiting clinical trials for Crohn's disease in the UK � from first-line immunosuppressants to advanced biologic and small-molecule therapies. See where trials fit into your treatment pathway.
Free to use � Live data from ClinicalTrials.gov � Updated daily
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Initial management of mild to moderate Crohn's disease
Standard: Aminosalicylates (5-ASAs), Budesonide, or dietary therapy (exclusive enteral nutrition)
When first-line therapy is insufficient or disease is moderate-to-severe
Standard: Azathioprine, 6-Mercaptopurine, Methotrexate, or systemic corticosteroids
For moderate-to-severe disease unresponsive to conventional therapy
Standard: Anti-TNF (Infliximab, Adalimumab), Vedolizumab, or Ustekinumab
After biologic failure � next-generation oral targeted therapies
Standard: Upadacitinib (JAK inhibitor), Risankizumab, or clinical trial
Complex disease including fistulae, strictures, or post-surgical recurrence
Standard: Combination therapy, stem cell therapy (trials), or surgical intervention
A type of inflammatory bowel disease (IBD) causing chronic inflammation of the digestive tract. Affects about 115,000 people in the UK. Can occur at any age but commonly starts between 15-40.
Up to 50% of Crohn's patients don't achieve lasting remission with current treatments. Research into new biologics, JAK inhibitors, microbiome therapies, and stem cell treatments offers hope for better outcomes.
About 20-40% of Crohn's patients develop fistulae � abnormal connections between organs. These are difficult to treat and clinical trials specifically targeting fistulising disease are particularly valuable.
Loading trials from ClinicalTrials.gov...
Novel approaches include oral small molecules (JAK inhibitors, S1P modulators), targeted biologics (anti-IL23, anti-TL1A), and microbiome-based therapies. Several are in Phase 3 trials in the UK.
Many trials recruit patients who have failed one biologic to test alternatives. Some study switching mechanisms of action (e.g., from anti-TNF to anti-IL23). Check individual trial criteria.
Yes. Some trials study specific exclusion diets, faecal microbiota transplantation (FMT), prebiotic and probiotic strategies, and personalised nutrition based on gut microbiome profiling.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.